Annovis Bio Stock Fundamentals
| ANVS Stock | USD 6.54 0.02 0.30% |
Annovis Bio fundamentals help investors to digest information that contributes to Annovis Bio's financial success or failures. It also enables traders to predict the movement of Annovis Stock. The fundamental analysis module provides a way to measure Annovis Bio's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Annovis Bio stock.
At this time, Annovis Bio's Selling General Administrative is comparatively stable compared to the past year. Gross Profit is likely to gain to about 263.2 K in 2024, despite the fact that Operating Income is likely to grow to (42.8 M). Annovis | Select Account or Indicator |
Annovis Bio Company Shares Owned By Insiders Analysis
Annovis Bio's Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
More About Shares Owned By Insiders | All Equity Analysis
Insiders Shares | = | Executives Shares | + | Employees |
Current Annovis Bio Shares Owned By Insiders | 20.40 % |
Most of Annovis Bio's fundamental indicators, such as Shares Owned By Insiders, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Annovis Bio is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.
| Competition |
Based on the latest financial disclosure, 20.4% of Annovis Bio are shares owned by insiders. This is 34.39% higher than that of the Biotechnology sector and 43.86% higher than that of the Health Care industry. The shares owned by insiders for all United States stocks is 102.18% lower than that of the firm.
Annovis Bio Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Annovis Bio's current stock value. Our valuation model uses many indicators to compare Annovis Bio value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Annovis Bio competition to find correlations between indicators driving Annovis Bio's intrinsic value. More Info.Annovis Bio is number one stock in return on equity category among its peers. It is rated third in return on asset category among its peers . At this time, Annovis Bio's Return On Equity is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Annovis Bio by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Annovis Shares Owned By Insiders Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Annovis Bio's direct or indirect competition against its Shares Owned By Insiders to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Annovis Bio could also be used in its relative valuation, which is a method of valuing Annovis Bio by comparing valuation metrics of similar companies.Annovis Bio is currently under evaluation in shares owned by insiders category among its peers.
Annovis Bio Current Valuation Drivers
We derive many important indicators used in calculating different scores of Annovis Bio from analyzing Annovis Bio's financial statements. These drivers represent accounts that assess Annovis Bio's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Annovis Bio's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 43.2M | 47.6M | 134.1M | 109.6M | 98.7M | 55.8M | |
| Enterprise Value | 43.6M | 39.5M | 88.4M | 81.2M | 73.1M | 44.9M |
Annovis Bio ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Annovis Bio's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Annovis Bio's managers, analysts, and investors.Environmental | Governance | Social |
Annovis Fundamentals
| Return On Equity | -5.97 | ||||
| Return On Asset | -1.55 | ||||
| Current Valuation | 77.87 M | ||||
| Shares Outstanding | 13.8 M | ||||
| Shares Owned By Insiders | 20.40 % | ||||
| Shares Owned By Institutions | 8.83 % | ||||
| Number Of Shares Shorted | 1.39 M | ||||
| Price To Earning | (0.43) X | ||||
| Price To Book | 12.81 X | ||||
| EBITDA | (45.04 M) | ||||
| Net Income | (56.2 M) | ||||
| Cash And Equivalents | 35.97 M | ||||
| Cash Per Share | 4.41 X | ||||
| Total Debt | 17.96 M | ||||
| Debt To Equity | (0.31) % | ||||
| Current Ratio | 28.11 X | ||||
| Book Value Per Share | 0.53 X | ||||
| Cash Flow From Operations | (39.97 M) | ||||
| Short Ratio | 4.02 X | ||||
| Earnings Per Share | (4.22) X | ||||
| Target Price | 34.8 | ||||
| Beta | 1.7 | ||||
| Market Capitalization | 90.51 M | ||||
| Total Asset | 10.21 M | ||||
| Retained Earnings | (110.26 M) | ||||
| Working Capital | 5.93 M | ||||
| Current Asset | 986 K | ||||
| Current Liabilities | 216 K | ||||
| Net Asset | 10.21 M |
About Annovis Bio Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Annovis Bio's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Annovis Bio using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Annovis Bio based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Cost Of Revenue | 10.3 K | 9.8 K |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Annovis Stock Analysis
When running Annovis Bio's price analysis, check to measure Annovis Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Annovis Bio is operating at the current time. Most of Annovis Bio's value examination focuses on studying past and present price action to predict the probability of Annovis Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Annovis Bio's price. Additionally, you may evaluate how the addition of Annovis Bio to your portfolios can decrease your overall portfolio volatility.